M
Mark J. Routbort
Researcher at University of Texas MD Anderson Cancer Center
Publications - 203
Citations - 7374
Mark J. Routbort is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Cancer. The author has an hindex of 42, co-authored 181 publications receiving 5702 citations. Previous affiliations of Mark J. Routbort include Duke University & College of American Pathologists.
Papers
More filters
Journal ArticleDOI
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials
Funda Meric-Bernstam,Lauren Brusco,Kenna R. Mills Shaw,Chacha Horombe,Scott Kopetz,Michael A. Davies,Mark J. Routbort,Sarina Anne Piha-Paul,Filip Janku,Naoto T. Ueno,David S. Hong,John de Groot,Vinod Ravi,Yisheng Li,Raja Luthra,Keyur P. Patel,Russell Broaddus,John Mendelsohn,Gordon B. Mills +18 more
TL;DR: Broad implementation of multiplex hotspot testing is feasible; however, only a small portion of patients with actionable alterations were actually enrolled onto genotype-matched trials, and the challenges for trial enrollment are reported.
Journal ArticleDOI
Clinical Validation of a Next-Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-Related Genes
Rajesh R. Singh,Keyur P. Patel,Mark J. Routbort,Neelima Reddy,Bedia A. Barkoh,Brian Handal,Rashmi Kanagal-Shamanna,Wesley O. Greaves,L. Jeffrey Medeiros,Kenneth D. Aldape,Rajyalakshmi Luthra +10 more
TL;DR: The IT-PGM platform with the ability to multiplex and simultaneously sequence multiple patient samples using low amounts of FFPE DNA was specific and sensitive for single nucleotide variant mutation analysis and can be incorporated easily into the clinical laboratory for routine testing.
Journal ArticleDOI
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
Courtney D. DiNardo,Farhad Ravandi,Sam Agresta,Marina Konopleva,Koichi Takahashi,Tapan M. Kadia,Mark J. Routbort,Keyur P. Patel,Mark Brandt,Sherry Pierce,Guillermo Garcia-Manero,Jorge E. Cortes,Hagop M. Kantarjian +12 more
TL;DR: This analysis defines the clinical outcome associated with IDH‐mutations in both the front‐line and salvage AML treatment settings, and confirms that response rate and OS for both IDh‐mutated and IDH wild‐type AML patients is comparable.
Journal ArticleDOI
Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes
Jonathan M. Loree,Allan Al Pereira,Michael Lam,Alexandra N. Willauer,Kanwal Pratap Singh Raghav,Arvind Dasari,Van K. Morris,Shailesh Advani,David G. Menter,Cathy Eng,Kenna R. Mills Shaw,Russell Broaddus,Mark J. Routbort,Yusha Liu,Jeffrey S. Morris,Rajyalakshmi Luthra,Funda Meric-Bernstam,Michael J. Overman,Dipen M. Maru,Scott Kopetz +19 more
TL;DR: Current right/left classifications may not fully recapitulate regional variations in tumor biology and the sigmoid-rectal region appears unique and the transverse colon is distinct from other right-sided locations.
Journal ArticleDOI
Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics
Rashmi Kanagal-Shamanna,Bryce P. Portier,Rajesh R. Singh,Mark J. Routbort,Kenneth D. Aldape,Brian Handal,Hamed Rahimi,Neelima Reddy,Bedia A. Barkoh,Bal Mukund Mishra,Abhaya Paladugu,Jawad Manekia,Neda Kalhor,Sinchita Roy Chowdhuri,Gregg A Staerkel,L. Jeffrey Medeiros,Rajyalakshmi Luthra,Keyur P. Patel +17 more
TL;DR: Next-generation sequencing can be performed with only nanograms of DNA and has better sensitivity than traditional sequencing platforms and enhances the power of fine needle aspiration by providing gene mutation results that can direct personalized cancer therapy.